Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclsoure Requirement), Regulation, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical has informed BSE that the Drugs Control Administration (DCA), Government of Telangana has suspended its manufacturing license permission for four products — Etoricoxib, Vildagliptin, Lacosamide, and Telmisartan — for a period of seven days starting from October 21, 2025. The suspension was ordered by the Office of the Deputy Director, DCA Nizamabad & Licensing Authority, after a Drug Inspector reported violations of certain Rules under the Drugs and Cosmetics Act, 1940 and Rules 1945. The underlying manufacturing license (No. 10/MD/AP/2013/B/G) remains valid until April 23, 2028, but the permission to produce these four specific products has been temporarily withdrawn. The company has disclosed a potential revenue loss of approximately Rs. 20 Lakhs for the suspension period.
The financial impact is small given the short 7-day duration and Rs. 20 lakh estimated loss, but the action highlights compliance concerns that could weigh on sentiment. Investors should monitor whether the suspension is extended or if further products are affected, as repeated regulatory actions could damage credibility with customers and regulators.